Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Miransertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 known ✓ | P31749 | 20/20 | 1.00 |
| ▸ | AKT2 known ✓ | P31751 | 8/20 | 1.00 |
| ▸ | AKT3 known ✓ | Q9Y243 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Miransertib SCHEMBL29852610 | 1.00 | AKT1 (1.00) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| Miransertib SCHEMBL29372652 | 0.99 | AKT1 (1.00) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| Miransertib SCHEMBL2187875 | 0.99 | AKT1 (1.00) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| Miransertib SCHEMBL30086167 | 0.99 | AKT1 (1.00) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| SCHEMBL25384343 | 0.95 | AKT1 (0.93) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| SCHEMBL31476762 | 0.95 | AKT1 (0.93) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| SCHEMBL2194123 | 0.93 | AKT1 (0.88) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| Miransertib SCHEMBL29638213 | 0.92 | AKT1 (0.87) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL2193628 | 0.92 | AKT1 (1.00) | AKT1AKT2AKT3CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL2191178 | 0.91 | AKT1 (1.00) | AKT1AKT2AKT3CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189036-B1 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATION DISORDERS | ARQULE INC (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-111494378-A | Compositions and methods for treating proliferative disorders | 艾科尔公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-107074769-B | Compositions and methods for treating proliferative disorders | 艾科尔公司 | 2020-04-07 | — | — | CN | disclosed |
| US-9949981-B2 | Compositions and methods for treating proliferation disorders | ARQULE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3189036-A1 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATION DISORDERS | ArQule, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016037044-A1 | COMPOSITIONS AND METHODS FOR TREATING PROLIFERATION DISORDERS | ARQULE, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
| US-20160067260-A1 | Compositions and Methods for Treating Proliferation Disorders | ARQULE, INC. | 2016-03-10 | — | — | US | disclosed |
| EP-2519522-B1 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE INC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8501770-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2519522-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067260-A1 | Compositions and Methods for Treating Proliferation Disorders | MKI67, HRAS, VHL | AKT1 2037/4885AKT2 1350/4885AKT3 1276/4885 |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | AKT1 2285/4885AKT2 1216/4885AKT3 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.